Carmell Therapeutics is addressing the burden of healing with its proprietary Plasma-based Bioactive Materials (PBM) technology
CARMELL RECEIVES FDA IND APPROVAL TO BEGIN PIVOTAL STUDY!
LAST MONEY IN OPPORTUNITY, $200K left of $8M bridge round to be converted at $20m. Company has term sheet for a preferred equity round with a $34.5M pre$ expected to close in January.
Carmell is a clinical development stage company that is on path to gain US FDA & EU regulatory approval for its first Plasma-based Bioactive Material product, Bone Healing Accelerant.